| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/09/2003 | WO2003002225A1 Nanoparticle structures |
| 01/09/2003 | WO2003002202A1 Antitumoral formulations of thioxanthenone |
| 01/09/2003 | WO2003002175A2 Enhanced systemic absorption of intradermally delivered substances |
| 01/09/2003 | WO2003002156A2 Contrast agents comprising metal particles encapsulated in microspheres for use in medical diagnostic imaging and therapy |
| 01/09/2003 | WO2003002153A1 Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins |
| 01/09/2003 | WO2003002152A2 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 01/09/2003 | WO2003002151A1 Oral pharmaceutical compositions with modified release of the active ingredient |
| 01/09/2003 | WO2003002149A2 Use of pigment such as e.g. titanium dioxide for obtaining a special optical effect on oral medicament or food |
| 01/09/2003 | WO2003002148A1 Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
| 01/09/2003 | WO2003002142A1 Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes |
| 01/09/2003 | WO2003002141A1 Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
| 01/09/2003 | WO2003002123A2 Therapeutic combinations for the treatment of hormone deficiencies |
| 01/09/2003 | WO2003002111A1 Inhalation particles |
| 01/09/2003 | WO2003002103A2 Hydrophobic dopamine agonists administered to the dermis |
| 01/09/2003 | WO2003002102A1 Sustained release pharmaceutical composition |
| 01/09/2003 | WO2003002101A1 Oral pharmaceutical compositions with improved bioavailability |
| 01/09/2003 | WO2003002100A1 Tamper-proof narcotic delivery system |
| 01/09/2003 | WO2003002099A1 Chewable product including active ingredient |
| 01/09/2003 | WO2003002098A1 Tablet comprising cetirizine and pseudoephedrine |
| 01/09/2003 | WO2003002097A1 Process of thermodynamical activation of water-insoluble drugs loaded into cross-linked polymers |
| 01/09/2003 | WO2003002096A1 Methods and compositions for polyene antibiotics with reduced toxicity |
| 01/09/2003 | WO2003002095A1 O/w type microemulsion preparation |
| 01/09/2003 | WO2003002094A2 Enhanced pharmacokinetic profile of hydrophobic substances |
| 01/09/2003 | WO2003002093A1 Olopatadine formulations for topical administration |
| 01/09/2003 | WO2003002092A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 01/09/2003 | WO2003002091A2 Sustained-release composition comprising lactic acid-glycolic acid copolymer and process for producing the same |
| 01/09/2003 | WO2003002065A2 Hcv e1e2 vaccine compositions |
| 01/09/2003 | WO2003002059A2 Tolterodine metabolites |
| 01/09/2003 | WO2002099457A8 Microchip devices with improved reservoir opening |
| 01/09/2003 | WO2002099026A8 Methods and formulations for enhancing the dissolution of a solid material in liquid |
| 01/09/2003 | WO2002098345A8 Use of an antioxidant for treating and/or preventing surface ocular disorders |
| 01/09/2003 | WO2002087642A3 Two-phase, water-absorbent bioadhesive composition |
| 01/09/2003 | WO2002083674A3 Compositions containing imidazotriazinone for nasal application |
| 01/09/2003 | WO2002080976A3 Hsa-free formulations of interferon-beta |
| 01/09/2003 | WO2002076376A3 A stable pharmaceutical composition of pravastatin |
| 01/09/2003 | WO2002069940A3 Highly flexible transdermal therapeutic system having nicotine as active substance |
| 01/09/2003 | WO2002064110A3 Carotenoid-loaded liposomes |
| 01/09/2003 | WO2002060486A3 Controlled release microsphere system for administration of drug to the eye |
| 01/09/2003 | WO2002053128A3 Sustained release drug delivery devices with multiple agents |
| 01/09/2003 | WO2002051443A3 Aqueous gel comprising a gelling agent such as kappa carrageenan and at least 85 % water |
| 01/09/2003 | WO2002051401A3 Controlled release formulations of divalproex sodium |
| 01/09/2003 | WO2002049622A3 Transdermal system containing a novel high potency progestagen |
| 01/09/2003 | WO2002043756A3 Method for obtaining antigenic aggregates and the use thereof in formulations |
| 01/09/2003 | WO2002038127A3 Particle formation methods and their products |
| 01/09/2003 | WO2002036097A3 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 01/09/2003 | WO2002034236A3 Lipid formulations for target delivery |
| 01/09/2003 | WO2002032943A3 Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
| 01/09/2003 | WO2002032398A3 Lipid-protein-sugar particles for drug delivery |
| 01/09/2003 | WO2002030388A3 Material for producing products having fibrinolytic and/or antibacterial properties |
| 01/09/2003 | WO2002020873A3 Method for precipitating mono and multiple layers of organophosphoric and organophosphonic acids and the salts thereof in addition to use thereof |
| 01/09/2003 | WO2002009716A3 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 01/09/2003 | WO2002005850A3 Enhancement of the action of anti-infective agents |
| 01/09/2003 | WO2002003970A2 Matrix controlled transdermal system for stabile derivatives of ace inhibitors |
| 01/09/2003 | WO2001064232A9 Use of avocado-soybean unsaponifiable preparations |
| 01/09/2003 | US20030009203 Ambulatory medical apparatus and method using a robust communication protocol |
| 01/09/2003 | US20030009145 Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space |
| 01/09/2003 | US20030009139 Adhesive sheet and adhesive preparation, and production methods thereof |
| 01/09/2003 | US20030009127 Implantable medical device with controllable gaseous agent release system |
| 01/09/2003 | US20030009004 For use in solubilization of insoluble drug and a delivery system of proteins, genes or drugs |
| 01/09/2003 | US20030008971 Hydrogel entrapping therapeutic agent and stent with coating comprising this |
| 01/09/2003 | US20030008904 For therapy of angina pectoris, atherosclerosis, hypertension and hyperlipidemia |
| 01/09/2003 | US20030008903 Administering to a human a therapeutically effective amount of optically pure R(+)isomer of lansoprazole, or a pharmaceutically acceptable salt for therapy of ulcers |
| 01/09/2003 | US20030008902 Paroxetine tablets & capsules |
| 01/09/2003 | US20030008900 Compounds and compositions for delivering active agents |
| 01/09/2003 | US20030008887 Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines |
| 01/09/2003 | US20030008852 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 01/09/2003 | US20030008851 Acne treatment including dual-package system |
| 01/09/2003 | US20030008835 Bioavailability of drug substance, are convenient to administer, and are stable |
| 01/09/2003 | US20030008827 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/09/2003 | US20030008819 Targeting endothelium for tissue-specific delivery of agents |
| 01/09/2003 | US20030008818 Compositions containing inclusion complexes |
| 01/09/2003 | US20030008813 Intracellular protein delivery compositions and methods of use |
| 01/09/2003 | US20030008810 Nutritional intervention composition for enhancing and extending satiety |
| 01/09/2003 | US20030008805 Comprises beta-adrenergic receptor agonist such as clenbuterol; improves tear secretion; reduced side effects on the heart |
| 01/09/2003 | US20030008396 Poly(vinyl alcohol) hydrogel |
| 01/09/2003 | US20030008040 Edible microcapsule and food containing the same |
| 01/09/2003 | US20030008022 Medical effect of jojoba oil |
| 01/09/2003 | US20030008019 Aqueous solution; efficient penetration |
| 01/09/2003 | US20030008015 Controlled drug delivery; anticancer agent |
| 01/09/2003 | US20030008014 Truncated apolipoprotein B-containing lipoprotein particles for delivery of compounds to tissues or cells |
| 01/09/2003 | US20030008013 Administering insulin to lungs |
| 01/09/2003 | US20030008012 Bactericide in solid form |
| 01/09/2003 | US20030008010 Aqueous suspension with good redispersibility |
| 01/09/2003 | US20030008008 Fast dissolving orally consumable films |
| 01/09/2003 | US20030008007 Release pharmaceutical construct for gastric retention |
| 01/09/2003 | US20030008006 Mixture of cabamazepine and water swellable polymer |
| 01/09/2003 | US20030008005 Sublingual administration of dihydroergotamine for the treatment of migraine |
| 01/09/2003 | US20030008004 Gabapentin; spray coating with binder solution; compression |
| 01/09/2003 | US20030008003 Compositions for enhanced absorption of NSAIDs |
| 01/09/2003 | US20030008002 Containing titanium dioxide platelets |
| 01/09/2003 | US20030008001 Process for cleaning hard gelatine capsules |
| 01/09/2003 | US20030008000 DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus |
| 01/09/2003 | US20030007994 Releasing estrogen and cyclodextrin |
| 01/09/2003 | US20030007992 Zero-order prolonged release coaxial implants |
| 01/09/2003 | US20030007991 Devices including protein matrix materials and methods of making and using thereof |
| 01/09/2003 | US20030007983 Two-hybrid assay that detects HIV-1 reverse transcriptase dimerization |
| 01/09/2003 | US20030007966 Adult respiratory distress syndrome |
| 01/09/2003 | US20030007963 Treatment of pompe's disease |
| 01/09/2003 | US20030007958 Mixture of silica, flow control agent and carrier; cyclooxygenase inhibitor, antiinflammatory agents |
| 01/09/2003 | US20030007947 Applying polymerizable monomer and fungicide; applying to mouth |